GlassScriptPhysician profile
Eliea Sneij
NPI 1326501123
$2,997.26
in general payments reported to CMS, 2019-2025
24 companies · $801 in 2025
The $801 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $115 · 2023: $592 · 2024: $1,489 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,882.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $689.91 | 2024-2025 | Impella |
| Medtronic, INC. | $491.72 | 2022-2024 | Linq II, Micra, Aurora Ev-Icd Mri Surescan |
| Shockwave Medical, INC | $320.26 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Inari Medical, INC. | $295.35 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boston Scientific Corporation | $247.64 | 2022-2024 | Watchman Flx, Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $196.07 | 2025 | Lifevest |
| Cvrx, INC. | $183.61 | 2024 | Barostim Neo System |
| Pfizer INC. | $157.15 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $65.81 | 2022-2025 | Farxiga, Wainua |
| Janssen Pharmaceuticals, INC | $49.05 | 2024 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $39.78 | 2024-2025 | Evkeeza |
| Inspire Medical Systems, INC. | $35.23 | 2025 | Inspire |
| Lexicon Pharmaceuticals, INC. | $34.50 | 2023 | Inpefa |
| Lantheus Medical Imaging, INC. | $22.56 | 2025 | |
| Alnylam Pharmaceuticals INC. | $19.20 | 2025 | Amvuttra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $19.04 | 2025 | Repatha |
| Scpharmaceuticals INC. | $19.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $18.90 | 2024 | Eliquis |
| Novo Nordisk INC | $17.79 | 2023 | |
| Merck Sharp & Dohme LLC | $16.77 | 2023 | Verquvo |
| Genzyme Corporation | $16.69 | 2025 | |
| Sanofi-Aventis U.S. LLC | $14.72 | 2023 | |
| Olympus America INC. | $14.00 | 2024 | Visera Elite II Video System Center |
| Altathera Pharmaceuticals LLC | $12.51 | 2025 | Sotalol Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eliea Sneij listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.